Type of Issue (IPO / FPO) ISsue Size (Rs. lakhs)* - Fresh Issue Size (Rs. lakhs)* - Fresh Issue Size (Rs. lakhs) - Source: Prospectus dated November 01, 20243 and Final Post issue report dated November 09, 2023 Grade of Issue along with name of the rating agency Not Applicable Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 *The above figure is after technical rejections QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars Qi (i) alloment in the issue (i) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)* (iv) at the end of 3rd FY (March 31, 2025)* - (v) at the end of 3rd FY (March 31, 2025)* **Boat of Source is after seporting for the relevant fiscal year has not been completed.		Name of the Issuer:	Maitreya Medicare Limited	Last updated on	15-Oct-24
- Fresh Issue Size (Rs. lakhs) *Source: Prospectus dated November 01, 20243 and Final Post issue report dated November 09, 2023 Grade of Issue along with name of the rating agency Name Grade Not Applicable Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 *The above figure is after technical rejections QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st Quarter immediately after the listing# (iv) at the end of 2nd FY (March 31, 2024)* (iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 3ft FY (March 31, 2026)* - (v) at the end of 3ft FY (March 31, 2026)*	1	Type of Issue (IPO / FPO)	IPO		
"Source: Prospectus dated November 01, 20243 and Final Post issue report dated November 09, 2023 Grade of issue along with name of the rating agency Name Grade Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 "The above figure is after technical rejections QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st EY (March 31, 2024)* (iv) at the end of 2nd FY (March 31, 2025)* (iv) at the end of 3nd FY (March 31, 2025)* (iv) at the end of 3nd FY (March 31, 2025)* (iv) at the end of 3nd FY (March 31, 2025)* (iv) at the end of 3nd FY (March 31, 2025)* (iv) at the end of 3nd FY (March 31, 2026)* AND Applicable Not	2	Issue Size (Rs. lakhs)*			
Grade of issue along with name of the rating agency Name Not Applicable Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 "The above figure is after technical rejections QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st Quarter immediately after the listing# (iv) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 3ft FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)* (v) at the end of 2nd FY (March 31, 2026)*		- Fresh Issue Size (Rs. lakhs)	1,489.12		
Name Grade Not Applicable Not Applicable Not Applicable 4 Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 *The above figure is after technical rejections 5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1 st C Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)* (iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 31, 2026)* - (v) at the end of 31, 2026)* - (v) at the end of 31, 2026)* - (v) at the end of 31, 2026)* - (v) at the end of 31, 2026)*		*Source: Prospectus dated November 01, 20243 and Final Post issue	report dated November 09, 2023		
Grade Not Applicable 4 Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 *The above figure is after technical rejections 5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)* (iv) at the end of 3rd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)* - (v) at the end of 3rd FY (March 31, 2026)* - - - - - - - - - - - - -	3	Grade of issue along with name of the rating agency			
Subscription Level (Number of times) Source: Final Post issue report dated November 09, 2023 "The above figure is after technical rejections GIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)* (iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 31, 2026)* Subscription Level (Number of times) 295.64* 295.64* 8 48 48 48 48 48 48 48 48 48 48 48 48		Name	Not Applicable		
Source: Final Post issue report dated November 09, 2023 "The above figure is after technical rejections GIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st Quarter immediately after the listing# (iv) at the end of 3rd FY (March 31, 2024)* (v) at the end of 3rd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)* -		Grade	Not Applicable		
Source: Final Post issue report dated November 09, 2023 "The above figure is after technical rejections GIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st Quarter immediately after the listing# (iv) at the end of 3rd FY (March 31, 2024)* (v) at the end of 3rd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)* -					
The above figure is after technical rejections GIB Holding (as a % of outstanding capital) as disclosed to stock exchanges Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024) (iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2025)* - (v) at the end of 3rd FY (March 31, 2025)*	4		295.64*		
Particulars %					
Particulars % (i) allotment in the issue (1) 4.86% (ii) at the end of 1st Quarter immediately after the listing# - (iii) at the end of 1st FY (March 31, 2024)* 3.87% (iv) at the end of 2nd FY (March 31, 2025)* - (v) at the end of 3rd FY (March 31, 2026)* -		*The above figure is after technical rejections			
Particulars % (i) allotment in the issue (1) 4.86% (ii) at the end of 1st Quarter immediately after the listing# - (iii) at the end of 1st FY (March 31, 2024)* 3.87% (iv) at the end of 2nd FY (March 31, 2025)* - (v) at the end of 3rd FY (March 31, 2026)* -	5				
(i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# - (iii) at the end of 1st FY (March 31, 2024)* 3.87% (iv) at the end of 2nd FY (March 31, 2025)* - (v) at the end of 3rd FY (March 31, 2026)* -	5	QIB Holding (as a % of outstanding capital) as disclosed to stoc	cexchanges		
(ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)* (iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)*	5		c exchanges		
(iii) at the end of 1st FY (March 31, 2024)* (iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)* -	5		<u>%</u>		
(iv) at the end of 2nd FY (March 31, 2025)* (v) at the end of 3rd FY (March 31, 2026)*	5	Particulars	<u>%</u>		
(v) at the end of 3rd FY (March 31, 2026)*	5	Particulars (i) allotment in the issue (1)	<u>%</u>		
	5	Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing#	% 4.86% -		
*# Data for December Quarter is not available *QIR Holding not disclosed as reporting for the relevant fiscal year has not been completed	5	Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)*	% 4.86% -		
	5	Particulars (i) allotment in the issue (1) (ii) at the end of 1st Quarter immediately after the listing# (iii) at the end of 1st FY (March 31, 2024)*	% 4.86% -		

Financials of the issuer (Consolidated)

			(In Rs.Crores)
Parameters	1st FY	2nd FY	3rd FY
raiaillelei5	(March 31, 2024)*	(March 31, 2025)*	(March 31, 2026)*
Income from operations	47.75	Not Available	Not Available
Net Profit for the period	2.76	Not Available	Not Available
Paid-up equity share capital	12.17	Not Available	Not Available
Reserves excluding revaluation reserves	18.08	Not Available	Not Available
*Financials not disclosed as reporting for the relevant fiscal year has not been completed.			_

Trading Status in the scrip of the issuer
Company's Equity Shares are listed on NSE EMERGE PLATFORM OF National Stock Exchange of India Limited

The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)*	Active
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

*Trading status not disclosed as the relevant fiscal year has not been completed.

Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)*	Not Available	Not Available
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

Source: Stock Exchange Filings

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document (ii) Actual implementation (iii) Reasons for delay in implementation, if any Not applicable Not applicable Not applicable

Status of utilization of issue proceeds (i) as disclosed in the offer document

Objects of the Fresh Issue Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Guiarat.	(Rs. lakhs)
'Maitreya Hospital	Amount
Private Limited' for setting up Hospital at Valsad, Gujarat.	750
Redemption of part of issued Non-Convertible Redeemable	100
Preference Shares	100
Funding the working capital requirements of the company	500
General Corporate Purpose	74.45
Total	1,424.45
Source: Prospectus dated November 01, 2023	

(ii) Actual utilization

		(Rs. lakhs)
Objects of the Fresh Issue		Amount
Making investment through Equity in the subsidiary named		
'Maitreya Hospital		194.24
Private Limited' for setting up Hospital at Valsad, Gujarat.		
Redemption of part of issued Non-Convertible Redeemable		34
Preference Shares		34
Funding the working capital requirements of the company		500
General Corporate Purpose		74.45
Total		1,424.45
(iii) Reasons for deviation, if any	Not applicable	

Comments of monitoring agency

mments on deviation, if any, in the use of proceeds of the rom the objects stated in the offer document	Not Applicable, since Issue size is less than Rs. 100 crores
other reservations expressed by the monitoring agency he end use of funds	

Pricing Data

Issue Price (Rs.): Designated Stock Exchange: Listing Date: 82 NSE 07-Nov-23

	At close of At close of 30th calendar day listing day from listing day		At close of 90th calendar day	As at the end of 1st FY after the listing of the issue		
Price parameters			from listing day		(March 31, 2024) ⁽³⁾	
·	(Nov 07, 2023)	(Dec 07, 2023) ⁽¹⁾	(Feb 05, 2024) ⁽²⁾	Closing price	High	Low
				51	(during the FY)	(during the FY)
Market Price on NSE	162.55	135.60	182.35	119.00	229.45	113.90
NIFTY50*	19,406.70	20,901.15	21,771.70	22,326.90	17,402.70	22,619.00
NIFTY Healthcare	9,677.05	10,338.65	11,566.95	12,059.30	14,971.80	9,198.30

Price parameters		Y after the listing of the issue rch 31, 2025)		As at the end of 3rd FY af	•	1
•	Closing price	High	Low	Clasina asias	High	Low
		(during the FY)	(during the FY)	Closing price	(during the FY)	(during the FY)
Market Price on NSE	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY Healthcare	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

*Being index of NSE, the designated stock exchange Note:

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
 (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
 (3) High and Low based on intra day prices
- (4) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Issue Price

4010 101 10040 1 1100					
Accounting ratio	Name of company	As disclosed in the offer document (See (9)(K) Schedule VI of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018)	At the end of 1 st FY March 31, 2024*	At the end of 2 nd FY March 31, 2025*	At the end of 2 nd FY March 31, 2026*
	Issuer:	7.93	Not Available	Not Available	Not Available
EPS	Peer Group: Shalby Limited	7.48	Not Available	Not Available	Not Available
	KMC Speciality Hospitals (India)	1.64	Not Available	Not Available	Not Available
	Industry Avg:	Not Available	Not Available	Not Available	Not Available
	Issuer:	10.34	Not Available	Not Available	Not Available
P/E	Peer Group: Shalby Limited	35.35	Not Available	Not Available	Not Available
=	KMC Speciality Hospitals (India) Limited	51.53	Not Available	Not Available	Not Available
	Industry Avg:	Not Available	Not Available	Not Available	Not Available
	Issuer:	45.49%	Not Available	Not Available	Not Available
RONW	Peer Group: Shalby Limited	7.30%	Not Available	Not Available	Not Available
W	KMC Speciality Hospitals (India) Limited	23.51	Not Available	Not Available	Not Available
	Industry Avg:	Not Available	Not Available	Not Available	Not Available
	Issuer	17.42	Not Available	Not Available	Not Available
	Peer Group: Shalby Limited	86.44	Not Available	Not Available	Not Available
NAV per share based on balance sheet	KMC Speciality Hospitals (India) Limited	6.96	Not Available	Not Available	Not Available
	Industry Avg:	Not Available	Not Available	Not Available	Not Available

Notes:

(1) Sourced from Prospectus dated January 03, 2024.

* The relevant data is not available yet.

**Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

- (i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.
- (ii) NAV per share Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal
- (iii) P/E Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement			
	NA .			

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by GYR Capital Advisors Private Limited ("GYR")arising out of the SEBI Master Circular No. SEBI/HO/CFD/PoD-1/P/CIR/2023/157 dated September 26, 2023. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE, Limited ("BSE" and the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, GYR does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein arising shall not be liable in any manner for the same. Neither GYR nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and viry or information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.